Two cases of risperidone-induced tardive dyskinesia and a review of the literature

European Psychiatry

Volumn 14, Issue 4, 1999, Pages 245-247

  Lykouras, L ^a   Yannakis, R ^a   Hatzimanolis, J ^a   Christodoulou, G N ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Risperidone; Tardive dyskinesia

Indexed keywords

HALOPERIDOL; RISPERIDONE; TRIFLUOPERAZINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INVOLUNTARY MOVEMENT; JAW MOVEMENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TARDIVE DYSKINESIA; TREATMENT PLANNING;

EID: 0033167828     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(99)80747-0     Document Type: Article

References (23)

1. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35.
2. Leyson J, Gommeren W, Ins A. Biochemical profile of risperidone: a novel antipsychotic. J Pharmacol Exp Therapeutics 1988; 247: 661-70.
3. Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. Psychopharmacology 1993; 110: 265-72.
4. Chouinard G, Jones B, Remington G, Bloom D, Addington D, Macewan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacology 1993; 13: 25-40.
5. Umbricht D, Kane JM. Medical complications of new antipsychotic drugs. Schizophr Bull 1996; 22: 475-83.
6. Kopala LC, Honer WG. Schizophrenia and severe tardive dyskinesia responsive to risperidone. J Clin Psychopharmacology 1994; 14: 439-41.
7. Chouinard G. Effect of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacology 1995; 15 Suppl 1: 36-44.
8. Addington DE, Towes JA, Addington JM. Risperidone and tardive dyskinesia (letter). Am J Psychiatry 1995; 56: 484-5.
9. Anand VS, Dewan MJ. Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Ann Clin Psychiatry 1996; 8: 179-82.
10. Buzan DR, Firestone D, Thomas M, Franklin DA. Risperidone-induced tardive dyskinesia (letter). Am J Psychiatry 1996; 153: 734-5.
11. Daniel GP, Smith K, Hyde T, Egan M. Neuroleptic-induced tardive dyskinesia (letter). Am J Psychiatry 1996; 153: 734.
12. Feeney DJ, Klykylo W. Risperidone and tardive dyskinesia (letter). J Am Child Adolesc Psychiatry 1996; 35: 1421-2.
13. Woarner MG, Sheitman BB, Lieberman JA, Kane JM. Tardive dyskinesia induced by risperidont? (letter). Am J Psychiatry 1996; 153: 843.
14. Hoberfellner EM. Tardive dyskinesia during treatment with risperidone (letter). Pharmacopsychiatry 1997; 30: 271.
15. Gwinn KA, Caviness JN. Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord 1997; 12: 119-21.
16. Sakkas P, Liappas J, Christodoulou GN. Tardive dyskinesia due to risperidone. Eur Psychiatry 1998; 13: 107-8.
17. Saran BM. Risperidone-induced tardive dyskinesia (letter). J Clin Psychiatry 1998; 59: 29-30.
18. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995; 152: 122-5.
19. Kane JM, Smith IM. Tardive dyskinesia: prevalence and risk factors 1959-1979. Arch Gen Psychiatry 1982; 39: 473-81.
20. Kane JM. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE, Kupfer AJ, eds. Psychopharmacology the fourth generation of progress. New York: Raven Press; 1995. p. 1485-95.
21. American Psychiatric Association Task Force on tardive dyskinesia. Tardive Diskinesia. Washington DC: American Psychiatric Association; 1992.
22. VanKammen DP, Marder SR. Dopamine receptors antagonists. In: Kaplan HI, Sadock BJ, eds. Comprehensive text book of psychiatry, 6th ed. Baltimore: Williams and Wilkins; 1995. p. 1782-2022.
23. Gutierez-Esteinou B, Grebb JA. Risperidone: an analysis of the first three years in general use. Intern Clin Psychopharmacology 1997; 12 Suppl 4: 3-10.